1. Apr 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
Randomized phase III trials are the gold standard of evidence-based drug development. They provide robust data on efficacy and safety and form the basis for regulatory decisions. However, with market approval, a new phase of evidence generation begins: the real-world...
4. Mar 2026 | B2B_Patient_Engagement, B2B_Patient-Reported Outcome., B2B_RWD
What Insights Digital Real-World Data Provide and Where Their Limits Lie Digital therapy companions are increasingly being discussed in the pharmaceutical industry as a potential source of patient insights. At the same time, it often remains unclear what kind of...
